Toward precision medicine with next-generation EGFR inhibitors in non-small-cell lung cancer.
about
Spotlight on afatinib and its potential in the treatment of squamous cell lung cancer: the evidence so farAfatinib for the treatment of metastatic non-small cell lung cancerOncDRS: An integrative clinical and genomic data platform for enabling translational research and precision medicineDiscovery and characterization of a novel irreversible EGFR mutants selective and potent kinase inhibitor CHMFL-EGFR-26 with a distinct binding mode.Next-Generation Covalent Irreversible Kinase Inhibitors in NSCLC: Focus on AfatinibCirculating Cell-Free Tumour DNA in the Management of Cancer.The development of precision medicine in clinical practice.Ibrutinib selectively and irreversibly targets EGFR (L858R, Del19) mutant but is moderately resistant to EGFR (T790M) mutant NSCLC CellsEGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6.Role of epidermal growth factor receptor in lung cancer and targeted therapies.Ibrutinib targets mutant-EGFR kinase with a distinct binding conformation.Clinical Implications of the T790M Mutation in Disease Characteristics and Treatment Response in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small-Cell Lung Cancer (NSCLC).Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Treatment of Metastatic Non-Small Cell Lung Cancer, with a Focus on AfatinibPrecision medicine: hype or hoax?Validation of liquid biopsy: plasma cell-free DNA testing in clinical management of advanced non-small cell lung cancer.Irreversible tyrosine kinase inhibition of epidermal growth factor receptor with afatinib in EGFR activating mutation-positive advanced non-small-cell lung cancer.Brain metastases in non-small-cell lung cancer: are tyrosine kinase inhibitors and checkpoint inhibitors now viable options?
P2860
Q26745776-BF2068DB-1A1D-4D94-80F3-1C3DB46DE55DQ28082181-2E2B4608-80CA-455A-AC58-62F018A3CC01Q31070571-495DF96D-BFCD-4F47-8E10-B2695DCBC84DQ33566948-F729CF10-3DC2-4004-9536-31CDF9F1814CQ35807946-AD1BAF45-CB3D-4A09-B27D-7967EA4ABE74Q35814162-ED1D18D3-19C4-444D-88F2-E56C0819A20CQ35991895-D847C91D-1AFA-4DDC-94C2-DE56DB6151E0Q36544565-C3BDB815-A7FA-4287-99C3-A0CBB806B008Q37592893-0F533774-2662-49B8-8C7C-CBED4848F417Q37679981-78BF7081-177A-4952-970D-A1E7C8B244D2Q37688439-19437347-9358-4B30-8816-E15E7C265F91Q38676692-A5F1D552-183F-476B-9D2E-96CD43B1F6C7Q39339545-F89F2AE0-9073-4A52-A098-4E8191BEC214Q42007563-EFD5F7F9-8DE6-4391-B77D-2862EEE3B69DQ48502619-5D79D217-5C4C-427B-B504-7B58A659F9E8Q55224621-BA2C43CF-67CE-49B4-AAFD-1F68B819A69EQ55429658-18407EF4-D784-463D-AB03-9DCB129D8E5F
P2860
Toward precision medicine with next-generation EGFR inhibitors in non-small-cell lung cancer.
description
2014 nî lūn-bûn
@nan
2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Toward precision medicine with ...... in non-small-cell lung cancer.
@ast
Toward precision medicine with ...... in non-small-cell lung cancer.
@en
Toward precision medicine with ...... in non-small-cell lung cancer.
@nl
type
label
Toward precision medicine with ...... in non-small-cell lung cancer.
@ast
Toward precision medicine with ...... in non-small-cell lung cancer.
@en
Toward precision medicine with ...... in non-small-cell lung cancer.
@nl
prefLabel
Toward precision medicine with ...... in non-small-cell lung cancer.
@ast
Toward precision medicine with ...... in non-small-cell lung cancer.
@en
Toward precision medicine with ...... in non-small-cell lung cancer.
@nl
P2860
P356
P1476
Toward precision medicine with ...... in non-small-cell lung cancer
@en
P2093
Timothy A Yap
P2860
P304
P356
10.2147/PGPM.S55339
P50
P577
2014-09-19T00:00:00Z